Q1 2022 Results
Company overview
Financial performance
CRM
Financial review
Immunology
Neuroscience
2022 priorities
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
Abbreviations
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Cosentyx® - IL-17A inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04209205 INVIGORATE-2 (CAIN457P12302)
Psoriatic Arthritis (PSA)
Phase 3
380
The proportion of subjects achieving American College of Rheumatology 50
(ACR50) response criteria
Secukinumab intravenous (i.v.) regimen
Placebo intravenous (i.v.) regimen
Patients with active psoriatic arthritis (PSA) despite current or previous NSAID,
DMARD and/or anti-TNF therapy
Target Patients
Read-out Milestone(s)
Publication
2023
H2-2021 (Actual)
NCT04300296 PRELUDE (CAIN457S12201)
Lichen Planus
Phase 2
108
Proportion of patients achieving Investigator's Global Assessment (IGA 0/1) score
at 16 weeks +30% delta vs placebo
Secukinumab 300 mg s.c.
Placebo s.c.
Adult patients with biopsy-proven lichen planus not adequately controlled by topical
therapies
2022
TBD
61 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation